Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI5395 plus Durvalumab in Advanced Solid Tumors
NCT03889275Phase 1Completed
- Sponsor
- MedImmune
- Start
- Oct 2019
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
Phase 1, open-label trial of MEDI5395 in solid tumor (advanced stage) (8 cohorts), sponsored by MedImmune. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) at 14.4 months, Number of Participants with Dose-limiting Toxicities at 28 days and 8 more. Started Oct 2019; status: completed.
02
Drugs
MEDI5395
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03889275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889275.